Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1

Interventions

pembrolizumab 42Specimen Handling 38Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 23Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15Paclitaxel 14Temozolomide 13Pemetrexed 13Docetaxel 13Cisplatin 13atezolizumab 12Ipilimumab 12Rituximab 11venetoclax 10Prednisone 10Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8X-Rays 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × quizartinib × 30 days × Clear all
NCT04128748 2026-06-02

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04687761 2026-05-13

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

PETHEMA Foundation

Phase 1/2 Completed
113 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡